nodes	percent_of_prediction	percent_of_DWPC	metapath
Praziquantel—CYP3A4—Thiotepa—urinary bladder cancer	0.0817	0.279	CbGbCtD
Praziquantel—CYP3A5—Etoposide—urinary bladder cancer	0.0568	0.194	CbGbCtD
Praziquantel—CYP1A2—Fluorouracil—urinary bladder cancer	0.0507	0.173	CbGbCtD
Praziquantel—CYP1A2—Etoposide—urinary bladder cancer	0.0423	0.145	CbGbCtD
Praziquantel—CYP2D6—Doxorubicin—urinary bladder cancer	0.0238	0.0812	CbGbCtD
Praziquantel—CYP3A4—Etoposide—urinary bladder cancer	0.0222	0.0757	CbGbCtD
Praziquantel—CYP3A4—Doxorubicin—urinary bladder cancer	0.0151	0.0517	CbGbCtD
Praziquantel—Bone disorder—Methotrexate—urinary bladder cancer	0.00219	0.0058	CcSEcCtD
Praziquantel—Abdominal discomfort—Cisplatin—urinary bladder cancer	0.00217	0.00574	CcSEcCtD
Praziquantel—Dizziness—Mitomycin—urinary bladder cancer	0.00215	0.00571	CcSEcCtD
Praziquantel—Cardiac disorder—Thiotepa—urinary bladder cancer	0.00214	0.00567	CcSEcCtD
Praziquantel—Immune system disorder—Thiotepa—urinary bladder cancer	0.00208	0.00552	CcSEcCtD
Praziquantel—Vomiting—Mitomycin—urinary bladder cancer	0.00207	0.00549	CcSEcCtD
Praziquantel—Arrhythmia—Thiotepa—urinary bladder cancer	0.00206	0.00546	CcSEcCtD
Praziquantel—Rash—Mitomycin—urinary bladder cancer	0.00205	0.00544	CcSEcCtD
Praziquantel—Dermatitis—Mitomycin—urinary bladder cancer	0.00205	0.00544	CcSEcCtD
Praziquantel—Bone disorder—Epirubicin—urinary bladder cancer	0.00205	0.00542	CcSEcCtD
Praziquantel—Headache—Mitomycin—urinary bladder cancer	0.00204	0.00541	CcSEcCtD
Praziquantel—Nausea—Mitomycin—urinary bladder cancer	0.00194	0.00513	CcSEcCtD
Praziquantel—Atrioventricular block—Epirubicin—urinary bladder cancer	0.00191	0.00505	CcSEcCtD
Praziquantel—Bone disorder—Doxorubicin—urinary bladder cancer	0.00189	0.00502	CcSEcCtD
Praziquantel—Bradycardia—Cisplatin—urinary bladder cancer	0.00184	0.00488	CcSEcCtD
Praziquantel—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.0018	0.00477	CcSEcCtD
Praziquantel—Atrioventricular block—Doxorubicin—urinary bladder cancer	0.00176	0.00467	CcSEcCtD
Praziquantel—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00175	0.00464	CcSEcCtD
Praziquantel—Convulsion—Thiotepa—urinary bladder cancer	0.00174	0.00461	CcSEcCtD
Praziquantel—Arrhythmia—Gemcitabine—urinary bladder cancer	0.00173	0.00459	CcSEcCtD
Praziquantel—Myalgia—Thiotepa—urinary bladder cancer	0.00171	0.00453	CcSEcCtD
Praziquantel—Arrhythmia—Fluorouracil—urinary bladder cancer	0.0017	0.00452	CcSEcCtD
Praziquantel—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.0017	0.0045	CcSEcCtD
Praziquantel—Cardiac disorder—Cisplatin—urinary bladder cancer	0.00168	0.00445	CcSEcCtD
Praziquantel—Immune system disorder—Cisplatin—urinary bladder cancer	0.00163	0.00433	CcSEcCtD
Praziquantel—Arrhythmia—Cisplatin—urinary bladder cancer	0.00162	0.00428	CcSEcCtD
Praziquantel—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00161	0.00426	CcSEcCtD
Praziquantel—Skin disorder—Thiotepa—urinary bladder cancer	0.00159	0.00422	CcSEcCtD
Praziquantel—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.00157	0.00415	CcSEcCtD
Praziquantel—Anorexia—Thiotepa—urinary bladder cancer	0.00156	0.00414	CcSEcCtD
Praziquantel—Cardiac disorder—Etoposide—urinary bladder cancer	0.00154	0.00407	CcSEcCtD
Praziquantel—Malaise—Gemcitabine—urinary bladder cancer	0.00152	0.00404	CcSEcCtD
Praziquantel—Immune system disorder—Etoposide—urinary bladder cancer	0.0015	0.00396	CcSEcCtD
Praziquantel—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00149	0.00396	CcSEcCtD
Praziquantel—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.00146	0.00387	CcSEcCtD
Praziquantel—Somnolence—Thiotepa—urinary bladder cancer	0.00146	0.00386	CcSEcCtD
Praziquantel—Convulsion—Fluorouracil—urinary bladder cancer	0.00144	0.00381	CcSEcCtD
Praziquantel—Myalgia—Gemcitabine—urinary bladder cancer	0.00144	0.00381	CcSEcCtD
Praziquantel—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00143	0.00378	CcSEcCtD
Praziquantel—Decreased appetite—Thiotepa—urinary bladder cancer	0.00142	0.00377	CcSEcCtD
Praziquantel—Discomfort—Gemcitabine—urinary bladder cancer	0.00142	0.00376	CcSEcCtD
Praziquantel—Malaise—Cisplatin—urinary bladder cancer	0.00142	0.00376	CcSEcCtD
Praziquantel—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00141	0.00375	CcSEcCtD
Praziquantel—Myalgia—Fluorouracil—urinary bladder cancer	0.00141	0.00375	CcSEcCtD
Praziquantel—Fatigue—Thiotepa—urinary bladder cancer	0.00141	0.00374	CcSEcCtD
Praziquantel—Discomfort—Fluorouracil—urinary bladder cancer	0.0014	0.0037	CcSEcCtD
Praziquantel—Convulsion—Cisplatin—urinary bladder cancer	0.00136	0.00361	CcSEcCtD
Praziquantel—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00135	0.00358	CcSEcCtD
Praziquantel—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00135	0.00358	CcSEcCtD
Praziquantel—Myalgia—Cisplatin—urinary bladder cancer	0.00134	0.00355	CcSEcCtD
Praziquantel—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00134	0.00355	CcSEcCtD
Praziquantel—Skin disorder—Gemcitabine—urinary bladder cancer	0.00134	0.00355	CcSEcCtD
Praziquantel—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00134	0.00355	CcSEcCtD
Praziquantel—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00133	0.00353	CcSEcCtD
Praziquantel—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00133	0.00352	CcSEcCtD
Praziquantel—Discomfort—Cisplatin—urinary bladder cancer	0.00132	0.00351	CcSEcCtD
Praziquantel—Anorexia—Gemcitabine—urinary bladder cancer	0.00131	0.00348	CcSEcCtD
Praziquantel—Urticaria—Thiotepa—urinary bladder cancer	0.0013	0.00345	CcSEcCtD
Praziquantel—Malaise—Etoposide—urinary bladder cancer	0.0013	0.00345	CcSEcCtD
Praziquantel—Vertigo—Etoposide—urinary bladder cancer	0.0013	0.00343	CcSEcCtD
Praziquantel—Abdominal pain—Thiotepa—urinary bladder cancer	0.0013	0.00343	CcSEcCtD
Praziquantel—Body temperature increased—Thiotepa—urinary bladder cancer	0.0013	0.00343	CcSEcCtD
Praziquantel—Anorexia—Fluorouracil—urinary bladder cancer	0.00129	0.00342	CcSEcCtD
Praziquantel—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00126	0.00334	CcSEcCtD
Praziquantel—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00126	0.00333	CcSEcCtD
Praziquantel—Convulsion—Etoposide—urinary bladder cancer	0.00125	0.00331	CcSEcCtD
Praziquantel—Skin disorder—Cisplatin—urinary bladder cancer	0.00125	0.00331	CcSEcCtD
Praziquantel—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00123	0.00327	CcSEcCtD
Praziquantel—Eosinophilia—Methotrexate—urinary bladder cancer	0.00123	0.00325	CcSEcCtD
Praziquantel—Somnolence—Gemcitabine—urinary bladder cancer	0.00123	0.00325	CcSEcCtD
Praziquantel—Anorexia—Cisplatin—urinary bladder cancer	0.00122	0.00324	CcSEcCtD
Praziquantel—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00122	0.00323	CcSEcCtD
Praziquantel—Discomfort—Etoposide—urinary bladder cancer	0.00121	0.00321	CcSEcCtD
Praziquantel—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00121	0.0032	CcSEcCtD
Praziquantel—Somnolence—Fluorouracil—urinary bladder cancer	0.0012	0.00319	CcSEcCtD
Praziquantel—Decreased appetite—Gemcitabine—urinary bladder cancer	0.0012	0.00317	CcSEcCtD
Praziquantel—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00119	0.00315	CcSEcCtD
Praziquantel—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00119	0.00315	CcSEcCtD
Praziquantel—Fatigue—Gemcitabine—urinary bladder cancer	0.00119	0.00315	CcSEcCtD
Praziquantel—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00118	0.00312	CcSEcCtD
Praziquantel—Asthenia—Thiotepa—urinary bladder cancer	0.00118	0.00311	CcSEcCtD
Praziquantel—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00117	0.0031	CcSEcCtD
Praziquantel—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00117	0.0031	CcSEcCtD
Praziquantel—Pruritus—Thiotepa—urinary bladder cancer	0.00116	0.00307	CcSEcCtD
Praziquantel—Eosinophilia—Epirubicin—urinary bladder cancer	0.00115	0.00304	CcSEcCtD
Praziquantel—Skin disorder—Etoposide—urinary bladder cancer	0.00114	0.00303	CcSEcCtD
Praziquantel—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00114	0.00301	CcSEcCtD
Praziquantel—Anorexia—Etoposide—urinary bladder cancer	0.00112	0.00297	CcSEcCtD
Praziquantel—Diarrhoea—Thiotepa—urinary bladder cancer	0.00112	0.00297	CcSEcCtD
Praziquantel—Decreased appetite—Cisplatin—urinary bladder cancer	0.00112	0.00296	CcSEcCtD
Praziquantel—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00112	0.00296	CcSEcCtD
Praziquantel—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00111	0.00294	CcSEcCtD
Praziquantel—Drowsiness—Methotrexate—urinary bladder cancer	0.00111	0.00293	CcSEcCtD
Praziquantel—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00109	0.00289	CcSEcCtD
Praziquantel—Dizziness—Thiotepa—urinary bladder cancer	0.00108	0.00287	CcSEcCtD
Praziquantel—Urticaria—Fluorouracil—urinary bladder cancer	0.00108	0.00285	CcSEcCtD
Praziquantel—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00107	0.00284	CcSEcCtD
Praziquantel—Eosinophilia—Doxorubicin—urinary bladder cancer	0.00106	0.00282	CcSEcCtD
Praziquantel—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00106	0.00281	CcSEcCtD
Praziquantel—Somnolence—Etoposide—urinary bladder cancer	0.00105	0.00277	CcSEcCtD
Praziquantel—Vomiting—Thiotepa—urinary bladder cancer	0.00104	0.00276	CcSEcCtD
Praziquantel—Drowsiness—Epirubicin—urinary bladder cancer	0.00103	0.00274	CcSEcCtD
Praziquantel—Rash—Thiotepa—urinary bladder cancer	0.00103	0.00274	CcSEcCtD
Praziquantel—Dermatitis—Thiotepa—urinary bladder cancer	0.00103	0.00273	CcSEcCtD
Praziquantel—Headache—Thiotepa—urinary bladder cancer	0.00103	0.00272	CcSEcCtD
Praziquantel—Decreased appetite—Etoposide—urinary bladder cancer	0.00102	0.00271	CcSEcCtD
Praziquantel—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00102	0.00269	CcSEcCtD
Praziquantel—Body temperature increased—Cisplatin—urinary bladder cancer	0.00102	0.00269	CcSEcCtD
Praziquantel—Fatigue—Etoposide—urinary bladder cancer	0.00101	0.00269	CcSEcCtD
Praziquantel—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000998	0.00265	CcSEcCtD
Praziquantel—Asthenia—Gemcitabine—urinary bladder cancer	0.000989	0.00262	CcSEcCtD
Praziquantel—Pruritus—Gemcitabine—urinary bladder cancer	0.000975	0.00258	CcSEcCtD
Praziquantel—Nausea—Thiotepa—urinary bladder cancer	0.000973	0.00258	CcSEcCtD
Praziquantel—Feeling abnormal—Etoposide—urinary bladder cancer	0.00097	0.00257	CcSEcCtD
Praziquantel—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000962	0.00255	CcSEcCtD
Praziquantel—Pruritus—Fluorouracil—urinary bladder cancer	0.000959	0.00254	CcSEcCtD
Praziquantel—Drowsiness—Doxorubicin—urinary bladder cancer	0.000957	0.00254	CcSEcCtD
Praziquantel—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000946	0.00251	CcSEcCtD
Praziquantel—Bradycardia—Epirubicin—urinary bladder cancer	0.000945	0.0025	CcSEcCtD
Praziquantel—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000943	0.0025	CcSEcCtD
Praziquantel—Urticaria—Etoposide—urinary bladder cancer	0.000935	0.00248	CcSEcCtD
Praziquantel—Abdominal pain—Etoposide—urinary bladder cancer	0.00093	0.00247	CcSEcCtD
Praziquantel—Body temperature increased—Etoposide—urinary bladder cancer	0.00093	0.00247	CcSEcCtD
Praziquantel—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000927	0.00246	CcSEcCtD
Praziquantel—Asthenia—Cisplatin—urinary bladder cancer	0.000922	0.00244	CcSEcCtD
Praziquantel—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000921	0.00244	CcSEcCtD
Praziquantel—Immune system disorder—Methotrexate—urinary bladder cancer	0.000896	0.00237	CcSEcCtD
Praziquantel—Dizziness—Fluorouracil—urinary bladder cancer	0.000896	0.00237	CcSEcCtD
Praziquantel—Diarrhoea—Cisplatin—urinary bladder cancer	0.000879	0.00233	CcSEcCtD
Praziquantel—Vomiting—Gemcitabine—urinary bladder cancer	0.000876	0.00232	CcSEcCtD
Praziquantel—Bradycardia—Doxorubicin—urinary bladder cancer	0.000875	0.00232	CcSEcCtD
Praziquantel—Rash—Gemcitabine—urinary bladder cancer	0.000869	0.0023	CcSEcCtD
Praziquantel—Dermatitis—Gemcitabine—urinary bladder cancer	0.000868	0.0023	CcSEcCtD
Praziquantel—Hypersensitivity—Etoposide—urinary bladder cancer	0.000867	0.0023	CcSEcCtD
Praziquantel—Headache—Gemcitabine—urinary bladder cancer	0.000863	0.00229	CcSEcCtD
Praziquantel—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000862	0.00228	CcSEcCtD
Praziquantel—Vomiting—Fluorouracil—urinary bladder cancer	0.000862	0.00228	CcSEcCtD
Praziquantel—Rash—Fluorouracil—urinary bladder cancer	0.000854	0.00226	CcSEcCtD
Praziquantel—Dermatitis—Fluorouracil—urinary bladder cancer	0.000854	0.00226	CcSEcCtD
Praziquantel—Headache—Fluorouracil—urinary bladder cancer	0.000849	0.00225	CcSEcCtD
Praziquantel—Asthenia—Etoposide—urinary bladder cancer	0.000844	0.00224	CcSEcCtD
Praziquantel—Immune system disorder—Epirubicin—urinary bladder cancer	0.000839	0.00222	CcSEcCtD
Praziquantel—Pruritus—Etoposide—urinary bladder cancer	0.000833	0.00221	CcSEcCtD
Praziquantel—Arrhythmia—Epirubicin—urinary bladder cancer	0.000829	0.0022	CcSEcCtD
Praziquantel—Nausea—Gemcitabine—urinary bladder cancer	0.000819	0.00217	CcSEcCtD
Praziquantel—Vomiting—Cisplatin—urinary bladder cancer	0.000817	0.00216	CcSEcCtD
Praziquantel—Rash—Cisplatin—urinary bladder cancer	0.00081	0.00215	CcSEcCtD
Praziquantel—Dermatitis—Cisplatin—urinary bladder cancer	0.000809	0.00214	CcSEcCtD
Praziquantel—Diarrhoea—Etoposide—urinary bladder cancer	0.000805	0.00213	CcSEcCtD
Praziquantel—Nausea—Fluorouracil—urinary bladder cancer	0.000805	0.00213	CcSEcCtD
Praziquantel—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000801	0.00212	CcSEcCtD
Praziquantel—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000797	0.00211	CcSEcCtD
Praziquantel—Malaise—Methotrexate—urinary bladder cancer	0.000779	0.00206	CcSEcCtD
Praziquantel—Dizziness—Etoposide—urinary bladder cancer	0.000778	0.00206	CcSEcCtD
Praziquantel—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000776	0.00206	CcSEcCtD
Praziquantel—Vertigo—Methotrexate—urinary bladder cancer	0.000776	0.00206	CcSEcCtD
Praziquantel—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000768	0.00203	CcSEcCtD
Praziquantel—Nausea—Cisplatin—urinary bladder cancer	0.000763	0.00202	CcSEcCtD
Praziquantel—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00075	0.00199	CcSEcCtD
Praziquantel—Convulsion—Methotrexate—urinary bladder cancer	0.000748	0.00198	CcSEcCtD
Praziquantel—Vomiting—Etoposide—urinary bladder cancer	0.000748	0.00198	CcSEcCtD
Praziquantel—Rash—Etoposide—urinary bladder cancer	0.000742	0.00197	CcSEcCtD
Praziquantel—Dermatitis—Etoposide—urinary bladder cancer	0.000741	0.00196	CcSEcCtD
Praziquantel—Headache—Etoposide—urinary bladder cancer	0.000737	0.00195	CcSEcCtD
Praziquantel—Myalgia—Methotrexate—urinary bladder cancer	0.000735	0.00195	CcSEcCtD
Praziquantel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00073	0.00194	CcSEcCtD
Praziquantel—Malaise—Epirubicin—urinary bladder cancer	0.000729	0.00193	CcSEcCtD
Praziquantel—Discomfort—Methotrexate—urinary bladder cancer	0.000727	0.00193	CcSEcCtD
Praziquantel—Vertigo—Epirubicin—urinary bladder cancer	0.000726	0.00192	CcSEcCtD
Praziquantel—Convulsion—Epirubicin—urinary bladder cancer	0.0007	0.00186	CcSEcCtD
Praziquantel—Nausea—Etoposide—urinary bladder cancer	0.000699	0.00185	CcSEcCtD
Praziquantel—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000694	0.00184	CcSEcCtD
Praziquantel—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000691	0.00183	CcSEcCtD
Praziquantel—Myalgia—Epirubicin—urinary bladder cancer	0.000688	0.00182	CcSEcCtD
Praziquantel—Skin disorder—Methotrexate—urinary bladder cancer	0.000685	0.00181	CcSEcCtD
Praziquantel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000683	0.00181	CcSEcCtD
Praziquantel—Discomfort—Epirubicin—urinary bladder cancer	0.00068	0.0018	CcSEcCtD
Praziquantel—Malaise—Doxorubicin—urinary bladder cancer	0.000674	0.00179	CcSEcCtD
Praziquantel—Vertigo—Doxorubicin—urinary bladder cancer	0.000672	0.00178	CcSEcCtD
Praziquantel—Anorexia—Methotrexate—urinary bladder cancer	0.000672	0.00178	CcSEcCtD
Praziquantel—Convulsion—Doxorubicin—urinary bladder cancer	0.000648	0.00172	CcSEcCtD
Praziquantel—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000647	0.00171	CcSEcCtD
Praziquantel—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000642	0.0017	CcSEcCtD
Praziquantel—Skin disorder—Epirubicin—urinary bladder cancer	0.000641	0.0017	CcSEcCtD
Praziquantel—Myalgia—Doxorubicin—urinary bladder cancer	0.000637	0.00169	CcSEcCtD
Praziquantel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000632	0.00168	CcSEcCtD
Praziquantel—Discomfort—Doxorubicin—urinary bladder cancer	0.000629	0.00167	CcSEcCtD
Praziquantel—Anorexia—Epirubicin—urinary bladder cancer	0.000629	0.00167	CcSEcCtD
Praziquantel—Somnolence—Methotrexate—urinary bladder cancer	0.000627	0.00166	CcSEcCtD
Praziquantel—Decreased appetite—Methotrexate—urinary bladder cancer	0.000613	0.00162	CcSEcCtD
Praziquantel—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000609	0.00161	CcSEcCtD
Praziquantel—Fatigue—Methotrexate—urinary bladder cancer	0.000608	0.00161	CcSEcCtD
Praziquantel—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000601	0.00159	CcSEcCtD
Praziquantel—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000599	0.00159	CcSEcCtD
Praziquantel—Skin disorder—Doxorubicin—urinary bladder cancer	0.000593	0.00157	CcSEcCtD
Praziquantel—Somnolence—Epirubicin—urinary bladder cancer	0.000586	0.00155	CcSEcCtD
Praziquantel—Anorexia—Doxorubicin—urinary bladder cancer	0.000582	0.00154	CcSEcCtD
Praziquantel—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000581	0.00154	CcSEcCtD
Praziquantel—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000576	0.00153	CcSEcCtD
Praziquantel—Decreased appetite—Epirubicin—urinary bladder cancer	0.000573	0.00152	CcSEcCtD
Praziquantel—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00057	0.00151	CcSEcCtD
Praziquantel—Fatigue—Epirubicin—urinary bladder cancer	0.000569	0.00151	CcSEcCtD
Praziquantel—Urticaria—Methotrexate—urinary bladder cancer	0.00056	0.00148	CcSEcCtD
Praziquantel—Body temperature increased—Methotrexate—urinary bladder cancer	0.000557	0.00148	CcSEcCtD
Praziquantel—Abdominal pain—Methotrexate—urinary bladder cancer	0.000557	0.00148	CcSEcCtD
Praziquantel—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000556	0.00147	CcSEcCtD
Praziquantel—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000544	0.00144	CcSEcCtD
Praziquantel—Somnolence—Doxorubicin—urinary bladder cancer	0.000543	0.00144	CcSEcCtD
Praziquantel—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000539	0.00143	CcSEcCtD
Praziquantel—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000531	0.00141	CcSEcCtD
Praziquantel—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000527	0.0014	CcSEcCtD
Praziquantel—Fatigue—Doxorubicin—urinary bladder cancer	0.000526	0.00139	CcSEcCtD
Praziquantel—Urticaria—Epirubicin—urinary bladder cancer	0.000524	0.00139	CcSEcCtD
Praziquantel—Body temperature increased—Epirubicin—urinary bladder cancer	0.000521	0.00138	CcSEcCtD
Praziquantel—Abdominal pain—Epirubicin—urinary bladder cancer	0.000521	0.00138	CcSEcCtD
Praziquantel—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000519	0.00138	CcSEcCtD
Praziquantel—Asthenia—Methotrexate—urinary bladder cancer	0.000506	0.00134	CcSEcCtD
Praziquantel—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000503	0.00133	CcSEcCtD
Praziquantel—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000499	0.00132	CcSEcCtD
Praziquantel—Pruritus—Methotrexate—urinary bladder cancer	0.000499	0.00132	CcSEcCtD
Praziquantel—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000486	0.00129	CcSEcCtD
Praziquantel—Urticaria—Doxorubicin—urinary bladder cancer	0.000485	0.00128	CcSEcCtD
Praziquantel—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000483	0.00128	CcSEcCtD
Praziquantel—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000483	0.00128	CcSEcCtD
Praziquantel—Diarrhoea—Methotrexate—urinary bladder cancer	0.000482	0.00128	CcSEcCtD
Praziquantel—Asthenia—Epirubicin—urinary bladder cancer	0.000473	0.00125	CcSEcCtD
Praziquantel—Pruritus—Epirubicin—urinary bladder cancer	0.000467	0.00124	CcSEcCtD
Praziquantel—Dizziness—Methotrexate—urinary bladder cancer	0.000466	0.00124	CcSEcCtD
Praziquantel—Diarrhoea—Epirubicin—urinary bladder cancer	0.000451	0.0012	CcSEcCtD
Praziquantel—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00045	0.00119	CcSEcCtD
Praziquantel—Vomiting—Methotrexate—urinary bladder cancer	0.000448	0.00119	CcSEcCtD
Praziquantel—Rash—Methotrexate—urinary bladder cancer	0.000444	0.00118	CcSEcCtD
Praziquantel—Dermatitis—Methotrexate—urinary bladder cancer	0.000444	0.00118	CcSEcCtD
Praziquantel—Headache—Methotrexate—urinary bladder cancer	0.000442	0.00117	CcSEcCtD
Praziquantel—Asthenia—Doxorubicin—urinary bladder cancer	0.000438	0.00116	CcSEcCtD
Praziquantel—Dizziness—Epirubicin—urinary bladder cancer	0.000436	0.00116	CcSEcCtD
Praziquantel—Pruritus—Doxorubicin—urinary bladder cancer	0.000432	0.00114	CcSEcCtD
Praziquantel—Vomiting—Epirubicin—urinary bladder cancer	0.000419	0.00111	CcSEcCtD
Praziquantel—Nausea—Methotrexate—urinary bladder cancer	0.000419	0.00111	CcSEcCtD
Praziquantel—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000419	0.00127	CbGpPWpGaD
Praziquantel—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000418	0.00111	CcSEcCtD
Praziquantel—Rash—Epirubicin—urinary bladder cancer	0.000416	0.0011	CcSEcCtD
Praziquantel—Dermatitis—Epirubicin—urinary bladder cancer	0.000416	0.0011	CcSEcCtD
Praziquantel—Headache—Epirubicin—urinary bladder cancer	0.000413	0.0011	CcSEcCtD
Praziquantel—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000413	0.00125	CbGpPWpGaD
Praziquantel—CYP3A7—Biological oxidations—GSTM1—urinary bladder cancer	0.000409	0.00124	CbGpPWpGaD
Praziquantel—Dizziness—Doxorubicin—urinary bladder cancer	0.000404	0.00107	CcSEcCtD
Praziquantel—CYP3A7—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000404	0.00122	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000402	0.00122	CbGpPWpGaD
Praziquantel—Nausea—Epirubicin—urinary bladder cancer	0.000392	0.00104	CcSEcCtD
Praziquantel—CYP3A43—Metabolism—TYMP—urinary bladder cancer	0.000389	0.00118	CbGpPWpGaD
Praziquantel—Vomiting—Doxorubicin—urinary bladder cancer	0.000388	0.00103	CcSEcCtD
Praziquantel—Rash—Doxorubicin—urinary bladder cancer	0.000385	0.00102	CcSEcCtD
Praziquantel—Dermatitis—Doxorubicin—urinary bladder cancer	0.000385	0.00102	CcSEcCtD
Praziquantel—Headache—Doxorubicin—urinary bladder cancer	0.000382	0.00101	CcSEcCtD
Praziquantel—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	0.00037	0.00112	CbGpPWpGaD
Praziquantel—Nausea—Doxorubicin—urinary bladder cancer	0.000363	0.000961	CcSEcCtD
Praziquantel—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000361	0.00109	CbGpPWpGaD
Praziquantel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000361	0.00109	CbGpPWpGaD
Praziquantel—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	0.000359	0.00109	CbGpPWpGaD
Praziquantel—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000356	0.00108	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—NAT2—urinary bladder cancer	0.000352	0.00107	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000351	0.00106	CbGpPWpGaD
Praziquantel—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000346	0.00105	CbGpPWpGaD
Praziquantel—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.00034	0.00103	CbGpPWpGaD
Praziquantel—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000331	0.001	CbGpPWpGaD
Praziquantel—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.00033	0.001	CbGpPWpGaD
Praziquantel—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.000322	0.000975	CbGpPWpGaD
Praziquantel—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000317	0.000962	CbGpPWpGaD
Praziquantel—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000305	0.000923	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—RRM2—urinary bladder cancer	0.000304	0.00092	CbGpPWpGaD
Praziquantel—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000296	0.000896	CbGpPWpGaD
Praziquantel—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000292	0.000884	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000289	0.000874	CbGpPWpGaD
Praziquantel—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000288	0.000874	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—HPGDS—urinary bladder cancer	0.000281	0.000852	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—ENO2—urinary bladder cancer	0.000281	0.000852	CbGpPWpGaD
Praziquantel—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.00028	0.000848	CbGpPWpGaD
Praziquantel—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000278	0.000844	CbGpPWpGaD
Praziquantel—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000275	0.000832	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—GSTZ1—urinary bladder cancer	0.000273	0.000827	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—GSTT1—urinary bladder cancer	0.000273	0.000826	CbGpPWpGaD
Praziquantel—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.00027	0.000818	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000267	0.00081	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000267	0.00081	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—GSTO2—urinary bladder cancer	0.000259	0.000784	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—NAT1—urinary bladder cancer	0.000259	0.000784	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000252	0.000764	CbGpPWpGaD
Praziquantel—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000249	0.000754	CbGpPWpGaD
Praziquantel—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000245	0.000744	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.00024	0.000727	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.00024	0.000727	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—UGT2B7—urinary bladder cancer	0.000237	0.000717	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000233	0.000707	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000233	0.000707	CbGpPWpGaD
Praziquantel—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000229	0.000694	CbGpPWpGaD
Praziquantel—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000229	0.000693	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—NQO1—urinary bladder cancer	0.000227	0.000687	CbGpPWpGaD
Praziquantel—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000226	0.000684	CbGpPWpGaD
Praziquantel—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000226	0.000683	CbGpPWpGaD
Praziquantel—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000223	0.000674	CbGpPWpGaD
Praziquantel—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000216	0.000654	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	0.000213	0.000645	CbGpPWpGaD
Praziquantel—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.00021	0.000637	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000209	0.000634	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000208	0.000631	CbGpPWpGaD
Praziquantel—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000207	0.000629	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000205	0.00062	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000205	0.00062	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	0.000201	0.000609	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	0.000197	0.000597	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	0.000196	0.000594	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000195	0.00059	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000195	0.00059	CbGpPWpGaD
Praziquantel—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000194	0.000588	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000193	0.000585	CbGpPWpGaD
Praziquantel—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000191	0.000579	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—GSTP1—urinary bladder cancer	0.000189	0.000573	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	0.000187	0.000566	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—NAT1—urinary bladder cancer	0.000187	0.000566	CbGpPWpGaD
Praziquantel—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000178	0.00054	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—TYMS—urinary bladder cancer	0.000176	0.000533	CbGpPWpGaD
Praziquantel—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000176	0.000532	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—GSTM1—urinary bladder cancer	0.000174	0.000526	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—NCOR1—urinary bladder cancer	0.000174	0.000526	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	0.000171	0.000518	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—GPX1—urinary bladder cancer	0.000166	0.000504	CbGpPWpGaD
Praziquantel—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000164	0.000498	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—ERCC2—urinary bladder cancer	0.000163	0.000495	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—TYMP—urinary bladder cancer	0.000157	0.000475	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	0.000154	0.000466	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—MTHFR—urinary bladder cancer	0.000154	0.000465	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	0.000152	0.000462	CbGpPWpGaD
Praziquantel—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.00015	0.000453	CbGpPWpGaD
Praziquantel—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000148	0.000447	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	0.000145	0.00044	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—NAT1—urinary bladder cancer	0.000145	0.000438	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	0.000145	0.000438	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000142	0.000431	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—NAT2—urinary bladder cancer	0.000142	0.000429	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	0.000142	0.000429	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.00014	0.000425	CbGpPWpGaD
Praziquantel—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000138	0.000417	CbGpPWpGaD
Praziquantel—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000136	0.000411	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000133	0.000403	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000133	0.000403	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	0.000132	0.0004	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—PPARG—urinary bladder cancer	0.000125	0.000377	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—RRM2—urinary bladder cancer	0.000122	0.000371	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000122	0.000368	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—CREBBP—urinary bladder cancer	0.00012	0.000362	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	0.000119	0.000361	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	0.000119	0.00036	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	0.000113	0.000343	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—ENO2—urinary bladder cancer	0.000113	0.000343	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—TYMP—urinary bladder cancer	0.000113	0.000343	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	0.000113	0.000341	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—NAT1—urinary bladder cancer	0.000113	0.000341	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	0.000112	0.000341	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000111	0.000336	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	0.00011	0.000333	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	0.00011	0.000332	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	0.000109	0.000332	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	0.000103	0.000313	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	0.000103	0.000312	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—NAT2—urinary bladder cancer	0.000102	0.00031	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	0.000101	0.000305	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—PTGS2—urinary bladder cancer	9.8e-05	0.000297	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	9.27e-05	0.000281	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	9.17e-05	0.000278	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—NQO1—urinary bladder cancer	9.13e-05	0.000277	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—RRM2—urinary bladder cancer	8.84e-05	0.000268	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.78e-05	0.000266	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	8.76e-05	0.000265	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—TYMP—urinary bladder cancer	8.76e-05	0.000265	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	8.69e-05	0.000263	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—NAT1—urinary bladder cancer	8.69e-05	0.000263	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—PTEN—urinary bladder cancer	8.54e-05	0.000259	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	8.53e-05	0.000259	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	8.41e-05	0.000255	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	8.19e-05	0.000248	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—ENO2—urinary bladder cancer	8.19e-05	0.000248	CbGpPWpGaD
Praziquantel—CYP3A43—Metabolism—EP300—urinary bladder cancer	8.15e-05	0.000247	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—TYMP—urinary bladder cancer	8.05e-05	0.000244	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	7.95e-05	0.000241	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	7.94e-05	0.000241	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—NAT2—urinary bladder cancer	7.92e-05	0.00024	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	7.62e-05	0.000231	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—NAT2—urinary bladder cancer	7.28e-05	0.000221	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	7.16e-05	0.000217	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—TYMS—urinary bladder cancer	7.08e-05	0.000215	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	7e-05	0.000212	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	7e-05	0.000212	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.84e-05	0.000207	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—RRM2—urinary bladder cancer	6.84e-05	0.000207	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—TYMP—urinary bladder cancer	6.82e-05	0.000207	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	6.76e-05	0.000205	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—GPX1—urinary bladder cancer	6.7e-05	0.000203	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—NQO1—urinary bladder cancer	6.6e-05	0.0002	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	6.59e-05	0.0002	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	6.58e-05	0.000199	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.55e-05	0.000199	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	6.33e-05	0.000192	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—ENO2—urinary bladder cancer	6.33e-05	0.000192	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.29e-05	0.000191	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—RRM2—urinary bladder cancer	6.29e-05	0.00019	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	6.19e-05	0.000187	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—NAT2—urinary bladder cancer	6.17e-05	0.000187	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	6.14e-05	0.000186	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.05e-05	0.000183	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	5.82e-05	0.000176	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—ENO2—urinary bladder cancer	5.82e-05	0.000176	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	5.65e-05	0.000171	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	5.51e-05	0.000167	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—RRM2—urinary bladder cancer	5.33e-05	0.000161	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—TYMP—urinary bladder cancer	5.27e-05	0.00016	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—TYMS—urinary bladder cancer	5.12e-05	0.000155	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—NQO1—urinary bladder cancer	5.1e-05	0.000155	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	5.06e-05	0.000153	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	5.06e-05	0.000153	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—PPARG—urinary bladder cancer	5.02e-05	0.000152	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.95e-05	0.00015	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	4.93e-05	0.000149	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—ENO2—urinary bladder cancer	4.93e-05	0.000149	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.9e-05	0.000149	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—GPX1—urinary bladder cancer	4.84e-05	0.000147	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	4.82e-05	0.000146	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	4.78e-05	0.000145	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.76e-05	0.000144	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	4.76e-05	0.000144	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.71e-05	0.000143	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—NQO1—urinary bladder cancer	4.69e-05	0.000142	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	4.47e-05	0.000135	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.32e-05	0.000131	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	4.26e-05	0.000129	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.12e-05	0.000125	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—RRM2—urinary bladder cancer	4.11e-05	0.000125	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.98e-05	0.00012	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—TYMS—urinary bladder cancer	3.96e-05	0.00012	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	3.95e-05	0.00012	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	3.91e-05	0.000119	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	3.91e-05	0.000118	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	3.91e-05	0.000118	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.86e-05	0.000117	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.81e-05	0.000115	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.81e-05	0.000115	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—GPX1—urinary bladder cancer	3.75e-05	0.000113	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.69e-05	0.000112	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	3.68e-05	0.000111	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—TYMS—urinary bladder cancer	3.64e-05	0.00011	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—PPARG—urinary bladder cancer	3.63e-05	0.00011	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	3.6e-05	0.000109	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	3.6e-05	0.000109	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	3.48e-05	0.000106	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	3.46e-05	0.000105	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3.45e-05	0.000104	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—PTEN—urinary bladder cancer	3.44e-05	0.000104	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	3.38e-05	0.000102	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.36e-05	0.000102	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	3.32e-05	0.0001	CbGpPWpGaD
Praziquantel—CYP3A7—Metabolism—EP300—urinary bladder cancer	3.28e-05	9.94e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.21e-05	9.72e-05	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	3.18e-05	9.63e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—TYMS—urinary bladder cancer	3.08e-05	9.34e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.07e-05	9.3e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	3.05e-05	9.23e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	3.05e-05	9.23e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.92e-05	8.84e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.87e-05	8.68e-05	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	2.85e-05	8.64e-05	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.8e-05	8.49e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.69e-05	8.16e-05	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2.69e-05	8.16e-05	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.58e-05	7.81e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.56e-05	7.75e-05	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—PTEN—urinary bladder cancer	2.49e-05	7.54e-05	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.48e-05	7.5e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.38e-05	7.21e-05	CbGpPWpGaD
Praziquantel—CYP3A5—Metabolism—EP300—urinary bladder cancer	2.37e-05	7.19e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.35e-05	7.13e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.35e-05	7.13e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.25e-05	6.82e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.21e-05	6.7e-05	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	2.21e-05	6.68e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.18e-05	6.62e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	2.1e-05	6.36e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.08e-05	6.3e-05	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.03e-05	6.14e-05	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.92e-05	5.83e-05	CbGpPWpGaD
Praziquantel—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.83e-05	5.56e-05	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.77e-05	5.36e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.72e-05	5.21e-05	CbGpPWpGaD
Praziquantel—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.69e-05	5.11e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.69e-05	5.11e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.62e-05	4.91e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.5e-05	4.54e-05	CbGpPWpGaD
Praziquantel—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.43e-05	4.33e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.33e-05	4.02e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.16e-05	3.5e-05	CbGpPWpGaD
Praziquantel—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.1e-05	3.34e-05	CbGpPWpGaD
